Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC

NCT06228924 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Arrhythmogenic Right Ventricular Cardiomyopathy

Interventions

GENETIC: TN-401

Sponsor

Tenaya Therapeutics